A Phase II Study with CPT-11 Plus Leucovorin and Bolus IV 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma

References

• Moertel C. G., Fleming T. R., MacDonald J. S., Haller D. G., Laurie J. A., Tangen C. M., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 1995; 122(5)321–326
   PubMed Web of Science ®Google Scholar
• Mamounas E. P., Rockette H., Jones J., Wieand S., Wickerham D. L., Fisher B., Workmark N. Comparative efficacy of adjuvant chemotherapy in patients with Dukes'B vs Dukes'C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). Proc. Am. Soc. Clin. Oncol. 1996; 14: 205
   Google Scholar
• Koehne C. H., Midgley R., Seymour M., Kerr D. J. Advanced colorectal cancer: which regimens should be recommend?. Ann. Oncol. 1999; 10(8)877–882
   PubMed Web of Science ®Google Scholar
• Bleiberg H. Colorectal cancer—is there an alternative to 5-FU?. Eur. J. Cancer 1997; 33(4)536–541
   PubMed Web of Science ®Google Scholar
• Scheithauer W., Rosen H., Kornek G. V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 1993; 306(6880)752–755
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J. Clin. Oncol. 1992; 10(6)896–903
   PubMed Web of Science ®Google Scholar
• Machover D. A comprehensive review of 5fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80(7)1179–1187
   PubMed Web of Science ®Google Scholar
• Labianca R., Pancera G., Luporini G. Factors influencing response rates for advanced colorectal cancer. Ann. Oncol. 1996; 7(9)901–906
   PubMed Web of Science ®Google Scholar
• De Gramont A., Bosset J. F., Milan C., Rougier P., Bouche O., Etienne P. L., Morvan F., Louvet C., Guillot T., Francois E., Bedenne L. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French intergroupstudy. J. Clin. Oncol. 1997; 15(2)808–815
   PubMed Web of Science ®Google Scholar
• Leichman C. G., Fleming T. R., Muggia F. M., Tangen C. M., Ardalan B., Doroshow J. H., Meyers F. J., Holcombe R. F., Weiss G. R., Mangalik A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a SWOG study. J. Clin. Oncol. 1995; 13(6)1303–1311
   PubMed Web of Science ®Google Scholar
• Aranda E., Diaz-Rubio E., Cervantes A., Anton-Torres A., Carrato A., Massuti T., Tabernero J. M., Sastre J., Tres A., Aparicio J., Lopez-Vega J. M., Barneto I., Garcia-Conde J. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann. Oncol. 1998; 9(7)727–731
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998; 16(1)301–308
   PubMed Web of Science ®Google Scholar
• Rougier P., Bugat R., Douillard J. Y., Culine S., Suc E., Brunet P., Becouarn Y., Ychou M., Marty M., Extra J. M., Bonneterre J., Adenis A., Seitz J. F., Ganem G., Namer M., Conroy T., Negrier S., Merrouche Y., Burki F., Mousseau M., Herait P., Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil–based chemotherapy. J. Clin. Oncol. 1997; 15(1)251–260
   PubMed Web of Science ®Google Scholar
• Aravantinos G., Skarlos D., Kosmidis P., Georgoulias V., Sgouros I., Bafaloukos D., Androulakis N., Florou S., Fountzilas G. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Crit. Rev. Hematol. Oncol. 1999; 32(3)209–219
   PubMed Web of Science ®Google Scholar
• Rougier P., Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Sem. Oncol. 1996; 23(1 suppl 3)34–41
   PubMed Web of Science ®Google Scholar
• Labianca R., Pessi M. A., Zamparelli G. The treatment of colorectal cancer. Drugs 1997; 53(4)593–607
   PubMedGoogle Scholar
• Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352(9138)1407–1412
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Douillard J., Pirotta N., Awad L., Elfring G. L., Gruia G., Locker P. K., Alakl M., Knight R. D., Miller L. L. Combined analysis of two phase III randomized trials comparing irinotecan, fluorouracil, leucovorin versus fluorouracil alone as first line therapy of previous untreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 242a
   Google Scholar
• Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal carcinoma: a multicenter randomised trial. Lancet 2000; 255(9209)1041–1047
   Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N., Elfring G. L., Miller L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000; 343(13)905–914
   PubMed Web of Science ®Google Scholar
• Maiello E., Gebbia V., Giuliani F., Paoletti G., Gebbia N., Cigolari S., Fortunato S., Pedicini T., Borsellino N., Lopez M., Colucci G. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann. Oncol. 2000; 11(8)1045–1051
   PubMed Web of Science ®Google Scholar
• Rothenberg M. L., Meropol N. J., Poplin E. A., Cutsem E. V., Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 2001; 19(18)3801–3807
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989; 10(1)1–10
   PubMedGoogle Scholar
• Saltz L. B., Kanowitz J., Kemeny N. E., Schaaf L., Spriggs D., Staton B. A., Berkery R., Steger C., Eng M., Dietz A., Locker P., Kelsen D. P. Phase I clinical and pharmacokinetics study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumours. J. Clin. Oncol. 1996; 14(11)2959–2967
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., Pozzo C., Starkhammar H., Dirix L., Terzoli E., Cognetti F., Humblet Y., Garufi C., Filez L., Gruia G., Cote C., Barone C. A phase II study of irinotecan alternated with five days bolus of 5fluorouracil and leucovorin first line chemotherapy of metastatic colorectal carcinoma. Ann. Oncol. 1998; 9(11)1199–1204
   PubMed Web of Science ®Google Scholar
• Ducreux M., Ychou M., Seitz J. F., Bonnay M., Bexon A., Armand J. P., Mahjoubi M., Mery-Mignard D., Rougier P. Irinotecan combined with bolus fluorouracil continuous infusion fluorouracil and high dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose finding and pharmacokinecic study in patients with pretreated metastatic colorectal cancer. J. Clin. Oncol. 1999; 17(9)2901–2908
   PubMed Web of Science ®Google Scholar
• Comella P., Casaretti R., De Vita F., Avallone A., Orditura M., Petrillo A., Gravina A., Faranda A., Comis S., Comella G., Catalano G. Concurrent irinotecan and 5fluorouracil plus levo-folinic acid given every other week in the first line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. Ann. Oncol. 1999; 10(8)915–921
   PubMed Web of Science ®Google Scholar
• Kalofonos H. P., Nicolaidis C., Samantas E., Mylonakis N., Aravantinos M. A., Dimopoulos M. A., Genatas C., Kouvatseas G., Giannoulis E., Dervenis C., Basdanis G., Pavlidis N., Androulakis J., Fountzilas G. A phase III study of 5fluorouracil versus 5fluorouracil plus leucovorin versus 5fluorouracil plus interferon a2b in patients with advanced colorectal cancer. Am. J. Clin. Oncol. 2002; 25(1)23–30
   PubMed Web of Science ®Google Scholar
• Kalofonos H. P., Papakostas P., Christodoulou C., Mylonakis N., Bamias A., Janinis J., Kourelis T. G., Xiros N., Papadimitriou C., Fountzilas G. A phase II trial with CPT-11, folinic acid and 5fluoruracil in patients with metastatic colorectal carcinoma. Proc. Am. Soc. Oncol. 2000; 19: 280a
   Google Scholar